These top stocks are on a winning streak and have the businesses to keep it going. The stock market continues to deliver growth opportunities for investors across a range of sectors. If you have cash to invest in great companies, you can consistently put it to work through market highs and lows as you work toward your long-term financial goals. Even if you have a modest amount to invest, strategies like dollar-cost averaging can help you grow your positions in your favorite stocks with time. You should only ...

Core Viewpoints - Hims & Hers Health shares dropped significantly after the FDA removed Eli Lilly's weight-loss drugs from its shortage list, impacting the company's ability to produce compounded versions [1] - The FDA's decision prohibits the production of compounded copycat drugs, which Hims & Hers has benefited from due to limited availability of original obesity medicines [1] - Hims & Hers shares fell 11 4% to $16 77 on Thursday, despite a year-to-date gain of nearly 90% [1] Company Performance - Hims & Hers Health shares experienced a sharp decline, dropping 11 4% to $16 77 in Thursday afternoon trading [1] - The company's shares have gained close to 90% since the start of the year, despite the recent drop [1] - Trading volume for Hims & Hers Health was 20 132 million on October 3, 2024 [2] Regulatory Impact - The FDA's removal of Eli Lilly's weight-loss drugs from its shortage list affects Hims & Hers' ability to produce compounded versions [1] - The FDA allows compounded drugs when original drugs are hard to obtain, but the latest decision restricts this for Eli Lilly's drugs [1] - This regulatory change could negatively impact Hims & Hers, which has benefited from the limited availability of certain obesity medicines [1] Market Context - Eli Lilly's weight-loss drugs, Mounjaro and Zepbound, are no longer on the FDA's shortage list, impacting competitors like Hims & Hers [1] - Earlier in August, Hims & Hers shares also declined after Eli Lilly announced cost-saving measures for its weight-loss drugs [1]

"We're in an asset bubble, and TQI can help you navigate it profitably" I am Ahan Vashi, a seasoned investor with professional background in equity research, private equity, and software engineering. I currently serve as the Chief Financial Engineer at The Quantamental Investor, a community pursuing financial freedom through bold, active investing with proactive risk management. TQI was established in July 2022 with a singular mission to make investing simple, fun, and profitable for all investors. In align ...

At PropNotes, we focus on finding top-notch, high-yield investment opportunities for individual investors. With our background in professional Prop Trading, we make complex concepts easy to understand and offer clear, actionable advice to help you achieve better returns. Occasionally, we will also share exclusive options strategies to help you enhance your performance even further. Every piece of content we produce is designed to help you make smart decisions in the market, backed by expert research you won ...

In the latest market close, Hims & Hers Health, Inc. (HIMS) reached $16.44, with a +0.86% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 0.28% for the day. Meanwhile, the Dow experienced a rise of 0.15%, and the technology-dominated Nasdaq saw an increase of 0.15%. Shares of the company have depreciated by 2.57% over the course of the past month, underperforming the Medical sector's gain of 0.38% and the S&P 500's gain of 2%. The investment community will b ...

Buying a new pharmacy will allow Hims & Hers to expand into new markets. Hims & Hers (HIMS -1.11%) recently acquired a pharmacy that will expand the company's product line and lower costs. This is the second major vertical integration for the company, and in this video Travis Hoium shows how it will continue to drive growth. *Stock prices used were end-of-day prices of Sept. 16, 2024. The video was published on Sept. 16, 2024. ...

Hims & Hers Health, Inc. (HIMS) ended the recent trading session at $16.28, demonstrating a -1.75% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.13% for the day. Meanwhile, the Dow experienced a rise of 0.55%, and the technology-dominated Nasdaq saw a decrease of 0.52%. The company's stock has climbed by 6.35% in the past month, exceeding the Medical sector's gain of 3.34% and the S&P 500's gain of 3.67%. The investment community will be payi ...

The healthcare company will be making more of the product it sells. Shares of healthcare company Hims & Hers Health (HIMS 2.85%) jumped as much as 23.9% this week after news of closing a large acquisition. According to data provided by S&P Global Market Intelligence, shares are up 18.3% for the week as of 2:30 p.m. ET. Hims & Hers gets deeper into compounding The biggest news was Hims & Hers issuing 976,341 shares of common stock to acquire Nivagen Pharmaceuticals, which does business as MedisourceRX. The c ...

Shares of Hims & Hers are falling even as the company has been posting some solid results. Hims & Hers Health (HIMS 4.01%) has built its brand up in recent years by focusing on offering its customers products related to sensitive issues such as hair loss and erectile dysfunction. And it is looking at other opportunities, such as weight loss, that can accelerate its already high rate of growth. This can make it a potentially exciting stock for growth investors to hold in their portfolios. But despite the opp ...

Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic. In early 2020, people around the world experienced a life-changing event as the COVID-19 pandemic struck. One of the biggest byproducts of that crisis was a near-overnight shift from the office to work from home. This dynamic followed social-distancing protocols issued by the Centers for Disease Control and Prevention (CDC). With many in the general population adopting this new way of working, it wasn't long befo ...